3.48
+0.09(+2.65%)
Currency In USD
Address
Modi’in Technology Park
Hevel Modi'in, 7177871
Israel
Phone
972 8 642 9100
Website
Sector
Healthcare
Industry
Biotechnology
Employees
79
First IPO Date
July 27, 2011
| Name | Title | Pay | Year Born |
| Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA | Chief Executive Officer | 598,000 | 1960 |
| Ms. Mali Zeevi CPA, CPA | Chief Financial Officer | 374,000 | 1976 |
| Dr. Ella Sorani Ph.D. | Chief Development Officer | 452,000 | 1968 |
| Ms. Holly W. May M.B.A. | President of BioLineRx USA | 710,000 | 1962 |
| Mr. John Lacey | Head of Corporate Communications & Investor Relations | 0 | N/A |
| Ms. Tsipi Keren-Lehrer B.Sc., L.L.B. | Head of BD & Strategic Advisor | 0 | N/A |
| Mr. Raziel Fried | Treasurer & Budgetary Control Director | 0 | N/A |
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.